曲妥珠单抗和帕妥珠单抗治疗转移性乳腺癌后发生肿瘤溶解综合征：一例报告
Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report.
作者信息
Baudon C, Duhoux F P, Sinapi I, Canon J L
机构信息
Oncology-Hematology Services, Grand Hôpital de Charleroi, 6000, Charleroi, Belgium.
Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Université catholique de Louvain, 1200, Brussels, Belgium.
出版信息
J Med Case Rep. 2016 Jun 16;10:178. doi: 10.1186/s13256-016-0969-5.
BACKGROUND
Tumor lysis syndrome is a rare and potentially fatal complication of oncologic treatments, especially in solid tumors. To the best of our knowledge, tumor lysis syndrome has never been reported after trastuzumab and pertuzumab combination therapy. Knowledge of risk factors and active prevention proceedings is of utmost importance to avoid fatal outcomes.
CASE PRESENTATION
We present the case of a chemo-naive 58-year-old Belgian woman developing hypovolemic shock and multiple organ failure due to tumor lysis syndrome after a single dose of trastuzumab and pertuzumab in the context of the treatment of a metastatic breast cancer and resulting in fatal outcome despite optimal management.
CONCLUSIONS
Considering that targeted cancer therapies become increasingly effective, oncologists should be extremely cautious when treating patients at high risk of tumor lysis syndrome, even if they are not treated with cytotoxic chemotherapy, and determine appropriate prophylaxis.
背景
肿瘤溶解综合征是肿瘤治疗中一种罕见且可能致命的并发症，尤其在实体瘤中。据我们所知，曲妥珠单抗和帕妥珠单抗联合治疗后从未有过肿瘤溶解综合征的报道。了解危险因素和积极的预防措施对于避免致命后果至关重要。
病例报告
我们报告了一名58岁未接受过化疗的比利时女性病例，该患者在转移性乳腺癌治疗过程中，单剂量使用曲妥珠单抗和帕妥珠单抗后因肿瘤溶解综合征发生低血容量性休克和多器官功能衰竭，尽管进行了最佳治疗仍导致死亡。
结论
鉴于靶向癌症治疗越来越有效，肿瘤学家在治疗有肿瘤溶解综合征高风险的患者时应极其谨慎，即使这些患者未接受细胞毒性化疗，并确定适当的预防措施。
Zotero 插件